A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing TumorsLisa A. King, Hans van Vliet|Cancer Immunology Research|2023Cited by 35
Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engagerLisa A. King|iScience|2024Cited by 5
PD-L1 directed bispecific Vδ2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironmentLisa A. King|Journal for ImmunoTherapy of Cancer|2025Cited by 3
Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansionLisa A. King|Frontiers in Oncology|2024Cited by 2